Last Updated : March 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Juluca | Dolutegravir rilpivirine | HIV infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Dupixent | dupilumab | atopic dermatitis | Do not reimburse | Complete | ||
Besponsa | Inotuzumab Ozogamicin | Acute Lymphoblastic Leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Lonsurf | Trifluridine and Tipiracil | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
Alecensaro | Alectinib | Locally advanced or metastatic ALK+ NSCLC (first line) | Reimburse with clinical criteria and/or conditions | Complete | ||
Symtuza | Darunavir/cobicistat/emtricitabine/tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Taltz | ixekizumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | ||
Duodopa | Levodopa / carbidopa (Drug Plan Submission) | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Probuphine | buprenorphine hydrochloride | Opioid drug dependence, treatment | Reimburse with clinical criteria and/or conditions | Complete |